Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Filing & Registration

Thumbnail
February 24, 2021

Hints of a quickening emerge in accelerated approval conversions

Thumbnail
February 22, 2021

Brainstorm’s go or no-go decision

Article image
Vantage logo
February 18, 2021

Lutonix not above board below the knee, says adcom

Article image
Vantage logo
January 26, 2021

Novartis’s Leqvio delay could last a year

Article image
Vantage logo
January 22, 2021

Apellis takes the complement fight to Astrazeneca

The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.

Article image
Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.

Article image
Vantage logo
December 16, 2020

A new setting for antigen testing

It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.

Article image
Vantage logo
December 16, 2020

Novartis’s Paragon perseverance pays off – perhaps

Article image
Vantage logo
December 14, 2020

There’s no place like home for Covid-19 testing

Article image
Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

As Biontech and Pfizer’s Covid-19 vaccine gets a positive US vote, delays for Sanofi, Glaxo and CSL show that top-speed drug development is the exception.

Article image
Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Yesterday’s analysis of data on Astra's Covid-19 vaccine suggests it might remain a non-Western option.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.